Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human RLY-4008 study in intrahepatic cholangiocarcinoma and other advanced solid tumors
NL-OMON60151Phase 2Completed
- Sponsor
- Elevar Therapeutics
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lirafugratinib in cholangiocarcinoma (CCA) and Nonhematologic neoplasms (4 arms), sponsored by Elevar Therapeutics. Primary endpoints: Maximum tolerated dose and recommended phase 2 dose, Overall safety profile and 2 more. Started Feb 2022; status: completed.
02
Drugs
lirafugratinib
03
Conditions
cholangiocarcinoma (CCA)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60151.